Compare Crispr Therapeutics AG (CRSP) vs Eni SpA (E) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Eni SpA — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while Eni SpA trades at $49.12 (market cap $71.95B). The key difference: Eni SpA is far larger — about 14.5× Crispr Therapeutics AG's market cap, and Eni SpA pays a 4.93% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | E | |
|---|---|---|
Market Cap | $4.97B | $71.95B |
Sector | Health | Energy |
52-Week High | $76.78 | $57.61 |
52-Week Low | $44.34 | $32.93 |
Enterprise Value | $3.32B | $90.86B |
Dividend Yield | — | 4.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Eni (E) trades at $49.44, up 3.6% with a bullish technical signal supported by moving averages. The stock shows attractive valuation with P/E of 21.81 and P/S of 0.8, though revenue has declined from $132.5B in 2022 to $82.15B in 2025. Recent strategic moves include lithium investments in Chile, fusion energy partnerships, and global gas portfolio expansion. The company maintains positive cash flow with $238M net cash flow in 2025 and pays a $0.63 dividend.
Eni presents a mixed outlook with strong diversification efforts offset by declining revenue trends. The stock offers value characteristics with below-market valuations and dividend income, but faces headwinds from volatile energy markets and execution risks in new ventures. Analyst consensus leans cautious with 62% hold ratings, suggesting patience may be warranted despite current bullish technical momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →
